Redmile Group, LLC - 10 Aug 2021 Form 4 Insider Report for Adagio Therapeutics, Inc. (IVVD)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Aug 2021, 21:01:30 UTC
Prior SEC filing
05 Aug 2021
Next SEC filing
04 Oct 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC

Key filing fact

Redmile Group, LLC filed Form 4 for Adagio Therapeutics, Inc. (IVVD) on 12 Aug 2021.

Key facts

  • This page summarizes Redmile Group, LLC's Form 4 filing for Adagio Therapeutics, Inc. (IVVD).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 12 Aug 2021, 21:01.

Change

  • Previous filing in this sequence was filed on 05 Aug 2021.
  • Current net transaction value: +$24,990,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IVVD transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+1,920,960
Change %
Price
Shares after
1,920,960
Date
10 Aug 2021
Ownership
See Footnote
Footnotes
F1, F2
IVVD transaction

Common Stock

Purchase

Transaction value
$24,990,000
Shares
+1,470,000
Change %
+77%
Price
$17.00*
Shares after
3,390,960
Date
10 Aug 2021
Ownership
See Footnote
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IVVD transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
$0
Shares
-1,920,960
Change %
-100%
Price
$0.000000*
Shares after
0
Date
10 Aug 2021
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
1,920,960
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The Series C preferred stock (the "Series C Preferred") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series C Preferred had no expiration date.

Footnote F2

The Series C Preferred are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and the reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .